Schroeder Mark S 4
4 · LABCORP HOLDINGS INC. · Filed Mar 30, 2026
Research Summary
AI-generated summary of this filing
Labcorp EVP Mark Schroeder Receives Performance Awards; Shares Withheld
What Happened
- Mark S. Schroeder, EVP, President Diagnostics & COO of Laboratory Corporation of America Holdings (Labcorp, ticker: LH), was issued performance-based awards totaling 12,272 shares on March 26, 2026 (two grants). To satisfy tax withholding obligations, 6,068 of those shares were withheld (disposed) at $268.38 per share, generating proceeds/value of $1,628,530. The grants themselves are recorded at $0.00 (award, code A).
Key Details
- Transaction date: March 26, 2026. Filing date: March 30, 2026 (timely, within required Form 4 window).
- Awards: 9,304 shares (granted per award dated Feb 7, 2023) and 2,968 shares (granted per award dated May 5, 2023) — total 12,272 shares acquired (code A, price $0.00).
- Withholding (tax): 4,600 shares and 1,468 shares withheld/disposed at $268.38 each (code F) for a combined value of $1,628,530 to cover tax obligations.
- Net shares delivered to insider after withholding: 6,204 shares (12,272 granted − 6,068 withheld).
- Footnotes: F1/F3 confirm these were performance awards covering the three-year performance period ended Dec 31, 2025; F2 indicates stock withholding to satisfy tax obligations.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Transaction codes: A = award/grant; F = tax withholding (not an open-market sale).
Context
- These were performance-based restricted stock/unit awards that vested based on a multi-year performance period. The withheld shares represent a withholding (cashless) to cover taxes and are routine administrative actions, not necessarily an indication of a deliberate sale of shares on the open market.
- The filing shows the award entries at $0.00 (typical for granted shares). The $268.38 per-share figure is the value used for the withheld shares, which implies an approximate total award value of ~$3.29M at that per-share price.
Insider Transaction Report
Form 4
Schroeder Mark S
EVP, Pres Diagnostics & COO
Transactions
- Award
Common Stock
[F1]2026-03-26+9,304→ 15,777.143 total - Tax Payment
Common Stock
[F2]2026-03-26$268.38/sh−4,600$1,234,548→ 11,177.143 total - Award
Common Stock
[F3]2026-03-26+2,968→ 14,145.143 total - Tax Payment
Common Stock
[F2]2026-03-26$268.38/sh−1,468$393,982→ 12,677.143 total
Footnotes (3)
- [F1]Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025.
Signature
/s/ Kathryn W. Kyle, Attorney-in-Fact for Mark S. Schroeder|2026-03-30